Knight Therapeutics Inc. (OTCMKTS:KHTRF) Sees Significant Increase in Short Interest

Knight Therapeutics Inc. (OTCMKTS:KHTRFGet Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 376,600 shares, an increase of 7.2% from the December 31st total of 351,200 shares. Based on an average trading volume of 1,900 shares, the days-to-cover ratio is presently 198.2 days.

Knight Therapeutics Stock Performance

Shares of OTCMKTS KHTRF opened at $3.77 on Tuesday. The stock’s fifty day moving average is $3.75 and its 200 day moving average is $3.99. Knight Therapeutics has a 52 week low of $3.48 and a 52 week high of $4.55.

About Knight Therapeutics

(Get Free Report)

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

Further Reading

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.